Facts
- HQ
- United States
- Sectors
- Venture capital, Finance
- Founded
- 1977
Seattle Biotech Tune Therapeutics Raises $175M to Advance Epigenetic Editing Trials for Chronic Hepatitis B
Seattle-based biotech startup Tune Therapeutics raised $175 million to support clinical trials of its epigenetic editing treatments for chronic Hepatitis B. The funding will aid development of therapies that control gene expression without altering DNA, leveraging technology developed at Duke University.
Tune Therapeutics launches with $40M to commercialize TEMPO epigenomic platform for tuning gene activity
Tune Therapeutics, a biotech based in Seattle and Durham, N.C., launched with $40 million to develop TEMPO, an epigenomic platform that locates and fine-tunes gene activity to treat rare single-gene disorders and more common conditions. The leadership includes co‑founders Charles Gersbach, Akira Matsuno, and Fyodor Urnov and several veterans of Seattle cell therapy companies.
Shape Therapeutics raises $112M to advance RNA-editing platform and AAV gene-delivery for neurological and genetic diseases
Seattle preclinical biotech Shape Therapeutics raised $112 million to develop RNA-editing and gene therapy technologies, including improved AAV delivery vectors and an RNA editing platform. The company, led by CEO and co-founder Francois Vigneault and leveraging work from co-founder Prashant Mali, aims to target neurological and genetic diseases such as Parkinson's, Alzheimer’s, alpha-1 antitrypsin deficiency, and Rett syndrome.
